scholarly journals SET Domains of Histone Methyltransferases Recognize ISWI-Remodeled Nucleosomal Species

2009 ◽  
Vol 30 (3) ◽  
pp. 552-564 ◽  
Author(s):  
Wladyslaw A. Krajewski ◽  
Joseph C. Reese

ABSTRACT The trithorax (trxG) and Polycomb (PcG) group proteins recognize and propagate inheritable patterns of gene expression through a poorly understood epigenetic mechanism. A distinguishing feature of these proteins is the presence of a 130-amino-acid methyltransferase domain (SET), which catalyzes the methylation of histones. It is still not clear how SET proteins distinguish gene expression states, how they are targeted, or what regulates their substrate specificity. Many SET domain-containing proteins show robust activity on core histones but relatively weak activity on intact nucleosomes, their physiological substrate. Here, we examined the binding of two SET domain-containing proteins, ALL1 and SET7, to chromatin substrates. The SET domains from these proteins bind and methylate intact nucleosomes poorly but can recognize disrupted nucleosomal structures associated with transcribed chromatin. Interestingly, the remodeling of dinucleosomes by the ISWI class of ATP-dependent chromatin remodeling enzymes stimulated the binding of SET domains to chromatin and the methylation of H3 within the nucleosome. Unexpectedly, dinucleosomes remodeled by SWI/SNF were poor substrates. Thus, SET domains can distinguish nucleosomes altered by these two classes of remodeling enzymes. Our study reveals novel insights into the mechanism of how SET domains recognize different chromatin states and specify histone methylation at active loci.

2020 ◽  
Vol 21 (18) ◽  
pp. 6816
Author(s):  
Alberto J. López ◽  
Julia K. Hecking ◽  
André O. White

Long-term memory formation requires coordinated regulation of gene expression and persistent changes in cell function. For decades, research has implicated histone modifications in regulating chromatin compaction necessary for experience-dependent changes to gene expression and cell function during memory formation. Recent evidence suggests that another epigenetic mechanism, ATP-dependent chromatin remodeling, works in concert with the histone-modifying enzymes to produce large-scale changes to chromatin structure. This review examines how histone-modifying enzymes and chromatin remodelers restructure chromatin to facilitate memory formation. We highlight the emerging evidence implicating ATP-dependent chromatin remodeling as an essential mechanism that mediates activity-dependent gene expression, plasticity, and cell function in developing and adult brains. Finally, we discuss how studies that target chromatin remodelers have expanded our understanding of the role that these complexes play in substance use disorders.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. SCI-5-SCI-5
Author(s):  
Jonathan D. Licht

Abstract Abstract SCI-5 Aberrant regulation of histone methylation is a recurrent theme in multiple myeloma, lymphoma, and other B-cell malignancies. MMSET Multiple myeloma SET domain (MMSET) is a histone methyltransferase (HMT) overexpressed as a result of the translocation t(4;14) and is present in about 15 percent of multiple myeloma patients. MMSET is a nuclear protein with multiple domains critical for gene regulation, including the SET domain, which encodes histone methyltransferase activity, and protein and DNA interaction domains, including PHD and PWWP domains. Overexpression of MMSET induces a global increase in H3K36 methylation with concomitant loss of global H3K27 methylation. Kinetic studies using isotopic labeling and mass spectroscopy demonstrate that this change in methylation is due to both an increase in the rate of methylation of H3K36 and an increase in the demethylation of H3K27. These changes cause physical loosening of the chromatin structure, demonstrated by an increase in micrococcal nuclease accessibility, changes in DNA damage response, and aberrant gene expression. The HMT activity of MMSET is essential for growth stimulation by MMSET, as shown by the fact that reexpression of MMSET in a t(4;14) myeloma cell line, in which the rearranged MMSET allele was disrupted by homologous recombination (KMS11-TKO), rescued growth only when the HMT activity of the protein was intact. The complete H3K36/H3K27 switch mediated by MMSET requires all PHD finger domains of the protein, the second PWWP domain, and the functional SET domain. For example, a single point mutation in one PHD domain abrogated chromatin binding, histone methylation, and growth stimulation by the protein. Furthermore, deletion of the PHD domain 4 was able to increase H3K36 methylation but unable to reduce H3K37 methylation, leading to only partial growth stimulation. Despite the global change in histone methylation in response to MMSET, microarray and RNA-Seq analysis showed that only ∼1000 genes are appreciably changed in response to MMSET. The basis of the specificity of differential gene expression is under investigation. For example, many genes activated by MMSET display a peak of H3K27me3 near the transcription start site in MMSET-low cells, which is absent in MMSET-overexpressing cells, displaced by a broad pattern of H3K36me2 modification. We also found a subset of genes repressed in response to MMSET overexpression. While H3K27 methylation is decreased on a genome-wide basis in MMSET-overexpressing cells, H3K27me3 levels at repressed genes were increased in association with increased occupancy by EZH2. These regions did not show an increase in H3K36 methylation and are enriched with GC-rich elements, representing putative polycomb complex recruitment sites. We hypothesize that the global increase in H3K36me2 and drop of H3K27me3 levels on many genes leads to the displacement of the PRC2 complex from lower-affinity sites to such higher-affinity loci. These modes of action likely considerably diverge from the normal role of MMSET and EZH2 in gene regulation. Similarly, EZH2 point mutations in lymphoma lead to global chromatin dysfunction and aberrant regulation of specific sets of genes, only some of which represent previously identified EZH2 targets. Collectively, oncogenic lesions in histone-modifying enzymes in myeloma and other lymphoid neoplasms need to be understood on their own terms, as the lessons learned from the normal function of these enzymes may not predict their activity in malignancy. Disclosures: Licht: Epizyme, Inc: Research Funding.


Endocrinology ◽  
2008 ◽  
Vol 149 (12) ◽  
pp. 5922-5931 ◽  
Author(s):  
Wan-Yee Tang ◽  
Retha Newbold ◽  
Katerina Mardilovich ◽  
Wendy Jefferson ◽  
Robert Y. S. Cheng ◽  
...  

Neonatal exposure of CD-1 mice to diethylstilbestrol (DES) or genistein (GEN) induces uterine adenocarcinoma in aging animals. Uterine carcinogenesis in this model is ovarian dependent because its evolution is blocked by prepubertal ovariectomy. This study seeks to discover novel uterine genes whose expression is altered by such early endocrine disruption via an epigenetic mechanism. Neonatal mice were treated with 1 or 1000 μg/kg DES, 50 mg/kg GEN, or oil (control) on d 1–5. One group of treated mice was killed before puberty on d 19. Others were ovariectomized or left intact, and killed at 6 and 18 months of age. Methylation-sensitive restriction fingerprinting was performed to identify differentially methylated sequences associated with neonatal exposure to DES/GEN. Among 14 candidates, nucleosomal binding protein 1 (Nsbp1), the gene for a nucleosome-core-particle binding protein, was selected for further study because of its central role in chromatin remodeling. In uteri of immature control mice, Nsbp1 promoter CpG island (CGI) was minimally methylated. Once control mice reached puberty, the Nsbp1 CGI became hypermethylated, and gene expression declined further. In contrast, in neonatal DES/GEN-treated mice, the Nsbp1 CGI stayed anomalously hypomethylated, and the gene exhibited persistent overexpression throughout life. However, if neonatal DES/GEN-treated mice were ovariectomized before puberty, the CGI remained minimally to moderately methylated, and gene expression was subdued except in the group treated with 1000 μg/kg DES. Thus, the life reprogramming of uterine Nsbp1 expression by neonatal DES/GEN exposure appears to be mediated by an epigenetic mechanism that interacts with ovarian hormones in adulthood.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 675-675
Author(s):  
Eva Martinez-Garcia ◽  
Relja Popovic ◽  
Dong-Joon Min ◽  
Christine Will ◽  
Julia Meyer ◽  
...  

Abstract Abstract 675 The multiple myeloma SET domain (MMSET) gene is fused to the immunoglobulin locus in t(4;14)-associated multiple myeloma, and MMSET levels are elevated in these patients relative to other myeloma cases and normal cells. MMSET contains several domains commonly found in chromatin regulators including the PHD domain, PWWP domain and SET domain; responsible for histone methyl transferase (HMT) activity. What histone residues are methylated by MMSET in vivo has been uncertain. A well-folded, highly active form of the MMSET SET domain made in bacteria was promiscuous, methylating the H3K36, H3K27 and H4K20 residues of native histone as well as itself. To determine how MMSET affects chromatin in vivo and to identify genes regulated by MMSET, we engineered t(4;14)+ KMS11 cells with a tetracycline-inducible shRNA, leading to a >90% decrease in MMSET expression. Upon loss of MMSET expression, there was a striking decrease of trimethylated histone 3, lysine 36 (H3K36me3), a mark of transcriptional elongation and repression of intragenic transcription. At the same time, loss of MMSET expression was associated with a strong increase in H3K27me3, a chromatin mark associated with gene repression. For gain-of-function studies, the overexpressed MMSET allele in KMS11 cells was disrupted by homologous recombination (KMS11-TKO). KMS11-TKO cells, stably infected with a retrovirus carrying MMSET, displayed high levels of H3K36me3 and loss of H3K27me3. A specific mutation (Y1118A) in the SET domain of MMSET, predicted from crystal structure models to be required for histone binding, abrogated HMT activity of MMSET in vitro. Accordingly expression of MMSET Y1118A in KMS11-TKO cells failed to increase H3K36me3 levels. Another mutant, F1177A actually increased H3K36me3 levels above those stimulated by wild-type MMSET itself, most likely due to an expanded “pocket” within the SET domain that removed steric obstacles to the conversion of H3K36 from the mono-methyl to tri-methyl state. Collectively, these data indicate that H3K36 is a major methylation target of MMSET in vivo. To determine the genes regulated by MMSET and the importance of histone methylation in MMSET action, we profiled gene expression in both gain and loss-of-function systems using Illumina HumanWG-6 v3.0 expression arrays. We compared these gene lists with the top 2000 genes bound by MMSET as determined in a ChIP-on-chip assay using NimbleGen 2.7kb promoter arrays. MMSET knockdown affected expression of 1845 genes (FC>1.5, p<0.05); 931 were upregulated and 914 had reduced expression levels. Among these, 192 genes were also bound by MMSET. Re-expression of MMSET in KMS11-TKO cells led to increased expression of 749 genes while 788 genes were downregulated; 176 of these genes were also bound by MMSET. There were 38 genes that were bound by MMSET and regulated in both systems, including BMF, BTG2 and TP53INP1. These genes implicated in apoptosis represent potential direct transcriptional targets of MMSET. Furthermore, functional annotation of genes bound and regulated by MMSET in either the knockdown or repletion system, using Ingenuity Pathway Analysis, showed enrichment of genes implicated in the regulation of cell death and the p53 pathway (e.g. BAX, BCL2, CASP6), the cell cycle (CCNE2, E2F2, TP53INP1, CDC25A) and integrin-mediated signaling (ACTB, CDC42, ITGAL). The effect of MMSET on integrin signaling is of interest given that loss of MMSET expression or repletion of KMS11-TKO cells with MMSET altered the adhesive and growth properties of KMS11 cells. Finally, gene expression changes were contrasted between re-expression of wild-type MMSET and catalytically inactive MMSET Y1118A. Strikingly, the Y1118A mutant, which was deficient in altering cell adhesion and which did not change bulk histone methylation, altered expression of 1209 genes, 50% overlapping with those regulated by wild-type MMSET. Genes regulated by MMSET and the SET domain mutant were enriched mostly in cellular metabolism pathways (FDPS, IDI1, MVK) suggesting that effects on the cell cycle, adhesion and p53 pathways required the HMT activity of MMSET. These data indicate that MMSET can regulate genes in a HMT dependent and independent manner. Furthermore, MMSET target genes may be both activated and repressed upon changes in MMSET levels, indicating a complex interplay with the transcriptional machinery, likely through interactions with other transcriptional co-factors. Disclosures: No relevant conflicts of interest to declare.


2019 ◽  
Vol 97 (4) ◽  
pp. 345-356 ◽  
Author(s):  
Stefania Ciafrè ◽  
Valentina Carito ◽  
Giampiero Ferraguti ◽  
Antonio Greco ◽  
George N. Chaldakov ◽  
...  

This work highlights recent studies in epigenetic mechanisms that play a role in alcoholism, which is a complex multifactorial disorder. There is a large body of evidence showing that alcohol can modify gene expression through epigenetic processes, namely DNA methylation and nucleosomal remodeling via histone modifications. In that regard, chronic exposure to ethanol modifies DNA and histone methylation, histone acetylation, and microRNA expression. The alcohol-mediated chromatin remodeling in the brain promotes the transition from use to abuse and addiction. Unravelling the multiplex pattern of molecular modifications induced by ethanol could support the development of new therapies for alcoholism and drug addiction targeting epigenetic processes.


2021 ◽  
Vol 29 ◽  
Author(s):  
Jorseth Rodelo Gutiérrez ◽  
Arturo René Mendoza Salgadoa ◽  
Marcio De Ávila Arias ◽  
Homero San- Juan- Vergara ◽  
Wendy Rosales Rada ◽  
...  

Abstract: DNA is packaged in rolls in an octamer of histones forming a complex of DNA and proteins called chromatin. Chromatin as a structural matrix of a chromosome and its modifications are nowadays considered relevant aspects for regulating gene expression, which has become of high interest in understanding genetic mechanisms regulating various diseases, including cancer. In various types of cancer, the main modifications are found to be DNA methylation in the CpG dinucleotide as a silencing mechanism in transcription, post-translational histone modifications such as acetylation, methylation and others that affect the chromatin structure, the ATP-dependent chromatin remodeling and miRNA-mediated gene silencing. In this review we analyze the main alterations in gene expression, the epigenetic modification patterns that cancer cells present, as well as the main modulators and inhibitors of each epigenetic mechanism and the molecular evolution of the most representative inhibitors, which have opened a promising future in the study of HAT, HDAC, non-glycoside DNMT inhibitors and domain inhibitors.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5097-5097
Author(s):  
Virginia Mara De Deus Wagatsuma ◽  
Luisa C A Koury ◽  
Silvia Elena Sánchez ◽  
Lorena Lobo Figueiredo Pontes ◽  
Fernanda Borges da Silva ◽  
...  

Abstract The Nuclear SET Domain (NSD) Protein Lysine Methyltransferases (KMT) family is composed of three members: NSD1/KMT3B, NSD2/WHSC1/MMSET and NSD3/WHSC1L1 which regulate gene expression through methylation of lysine 36 of histone H3 (H3K36). NSD2 overexpression was reported in multiple myeloma with t(4;14)/IgH-MMSET. NSDs gene expression profile is unknown in acute leukemias, however NSD1 and NSD3 were described to be fused with the nucleoporin 98 gene (NUP98) in rare AML and myelodysplastic syndrome cases and, both fusion proteins were associated with poor prognosis. The aims of the present study were to characterize the expression of NSD-KMTs in patients with AML and healthy controls, to determine if this expression is associated with specific genetic abnormalities and/or with treatment outcome.A total of four healthy donors and 45 AML patients (27♀, 18♂) at diagnosis were included in the study. Our cohort included 8 patients with acute promyelocytic leukemia (APL), 8 with core binding factor (CBF) leukemias [4 with t(8;21) and 4 with inv(16)], and 29 patients with non-APL non-CBF AML. NSD family gene expression was evaluated by qPCR using the comparative Ct method for analysis. A higher expression of the NSD1 gene was observed in AML cells compared to normal bone marrow (BM) samples {median [range] = 3.202 [0.6804-0.096] vs. 1.003 [:0.7956-1.265], p=0.0243}. Similarly, the expression of NSD3 was higher in AML, but the difference was significant only for the comparison between healthy BM and CBF-AML groups {median [range] = 1.070 [0.6360-1.410] vs. 2.719 [1.238-8.830], p=0.0265}. No significant differences were detected in the analysis of NSD2 expression. Considering the three groups of AML patients, no correlation was found between NSD1, NSD2 or NSD3 expression levels and age, gender, leukocyte counts at diagnosis, karyotype (normal vs. abnormal), frequency of specific genetic abnormalities (t(15;17)/PML-RARA; t(8;21)/RUNX1-RUNX1T1; inv(16)/CBFB-MYH11) or percentage of blasts in bone marrow. NPM1 mutations and FLT3 internal tandem duplications (FLT3-ITD) were detected in 29.6% (13/44) and 21% (9/43) of the patients with AML, respectively. We observed a significant increase in NSD1, NSD2 and NSD3 expression in blasts from patients with FLT3-ITD (p=0.0177), but not in those with NPM1 mutations. These differences remained significant when APL cases were excluded from the analysis. Next, patients were grouped according to NSD1 or NSD2 expression. Patients with NSD1 or NSD2 expression higher or lower than the median value (3.25 and 3.16, respectively), showed no significant differences regarding age distribution, leukocyte counts or percentage of blasts in bone marrow at diagnosis, or presence of genetic abnormalities. Regarding the analysis of treatment outcome, patients with non-APL AML were stratified into high and low NSD1 or NSD2 expression subgroups using the criteria above. The median overall survival of patients in the low NSD2 expression subgroup was of 333,023 days [95% CI:158,541-507,505 days] whereas patients in the high NSD2 expression subgroup was of 817,629 days [95% CI:238,702-1396,555 days] (p=0,633). No significant difference observed between the overall survival of patients in the high and low NSD1 expression subgroups. In order to determine if NSD-KMT levels were associated with changes at histone H3 lysine 4 (H4K4) and H3K36 (known to activate gene transcription), as well at histone H3 lysine 9 (H3K9), H3K27, H3K79 and H4K29, associated to regulatory repression, we ran an experiment using Illumina Infinium Methylation 450k arrays. The comparison between normal and leukemic cells revealed specific histone methylation profiles. There is experimental evidence that histone methylation is a prerequisite for DNA methylation and transcriptional regulation, suggesting interplay between histone and DNA methylation. Our data correlate overexpression levels of NSD-KMT with histone modifications, suggesting that this modification and not only DNA methylation can contribute for epigenomic changes associated to AML pathogenesis. Disclosures No relevant conflicts of interest to declare.


2020 ◽  
Vol 27 (33) ◽  
pp. 5530-5542
Author(s):  
Xiaoqing Ye ◽  
Gang Chen ◽  
Jia Jin ◽  
Binzhong Zhang ◽  
Yinda Wang ◽  
...  

Mixed Lineage Leukemia 1 (MLL1), an important member of Histone Methyltransferases (HMT) family, is capable of catalyzing mono-, di-, and trimethylation of Histone 3 lysine 4 (H3K4). The optimal catalytic activity of MLL1 requires the formation of a core complex consisting of MLL1, WDR5, RbBP5, and ASH2L. The Protein-Protein Interaction (PPI) between WDR5 and MLL1 plays an important role in abnormal gene expression during tumorigenesis, and disturbing this interaction may have a potential for the treatment of leukemia harboring MLL1 fusion proteins. In this review, we will summarize recent progress in the development of inhibitors targeting MLL1- WDR5 interaction.


Genes ◽  
2021 ◽  
Vol 12 (4) ◽  
pp. 520
Author(s):  
Wenfeng Nie ◽  
Jinyu Wang

As essential structural components of ATP-dependent chromatin-remodeling complex, the nucleolus-localized actin-related proteins (ARPs) play critical roles in many biological processes. Among them, ARP4 is identified as an integral subunit of chromatin remodeling complex SWR1, which is conserved in yeast, humans and plants. It was shown that RNAi mediated knock-down of Arabidopsis thaliana ARP4 (AtARP4) could affect plant development, specifically, leading to early flowering. However, so far, little is known about how ARP4 functions in the SWR1 complex in plant. Here, we identified a loss-of-function mutant of AtARP4 with a single nucleotide change from glycine to arginine, which had significantly smaller leaf size. The results from the split luciferase complementation imaging (LCI) and yeast two hybrid (Y2H) assays confirmed its physical interaction with the scaffold and catalytic subunit of SWR1 complex, photoperiod-independent early flowering 1 (PIE1). Furthermore, mutation of AtARP4 caused altered transcription response of hundreds of genes, in which the number of up-regulated differentially expressed genes (DEGs) was much larger than those down-regulated. Although most DEGs in atarp4 are related to plant defense and response to hormones such as salicylic acid, overall, it has less overlapping with other swr1 mutants and the hta9 hta11 double-mutant. In conclusion, our results reveal that AtARP4 is important for plant growth and such an effect is likely attributed to its repression on gene expression, typically at defense-related loci, thus providing some evidence for the coordination of plant growth and defense, while the regulatory patterns and mechanisms are distinctive from other SWR1 complex components.


Sign in / Sign up

Export Citation Format

Share Document